We are live on ! Find out more
CRL icon

Charles River Laboratories

627 hedge funds and large institutions have $10.3B invested in Charles River Laboratories in 2024 Q3 according to their latest regulatory filings, with 66 funds opening new positions, 204 increasing their positions, 273 reducing their positions, and 97 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.76% less ownership

Funds ownership: 101.73%100.97% (-0.76%)

5% less capital invested

Capital invested by funds: $10.8B → $10.3B (-$568M)

6% less funds holding

Funds holding: 664627 (-37)

25% less funds holding in top 10

Funds holding in top 10: 86 (-2)

25% less repeat investments, than reductions

Existing positions increased: 204 | Existing positions reduced: 273

32% less first-time investments, than exits

New positions opened: 66 | Existing positions closed: 97

38% less call options, than puts

Call options by funds: $59M | Put options by funds: $94.8M

Holders
627
Holders Change
-37
Holders Change %
-5.57%
% of All Funds
9%
Holding in Top 10
6
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-25%
% of All Funds
0.09%
New
66
Increased
204
Reduced
273
Closed
97
Calls
$59M
Puts
$94.8M
Net Calls
-$35.8M
Net Calls Change
-$26.6M
Name Holding Trade Value Shares
Change
Change in
Stake
DILIC
376
Dai-ichi Life Insurance Company
Japan
$479K -$208K -1,000 -29%
ET
377
Equitable Trust
Tennessee
$477K -$8.94K -43 -2%
TC
378
Truvestments Capital
Florida
$474K +$72.7K +350 +17%
NG
379
Norden Group
Utah
$466K +$205K +986 +71%
SI
380
Sapience Investments
California
$463K
WMG
381
WESCAP Management Group
California
$463K +$34.9K +168 +8%
Public Sector Pension Investment Board (PSP Investments)
382
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
$449K +$62.3K +300 +15%
BAM
383
Blueshift Asset Management
New Jersey
$446K +$471K +2,264 New
AAS
384
Avantax Advisory Services
Texas
$435K -$27K -130 -6%
DM
385
Deerfield Management
New York
$434K +$458K +2,204 New
SG Americas Securities
386
SG Americas Securities
New York
$433K -$6.13M -29,506 -93%
BCV
387
Banque Cantonale Vaudoise
Switzerland
$425K -$15.2K -73 -3%
IB
388
Intrust Bank
Kansas
$424K +$32.8K +158 +8%
NB
389
Norinchukin Bank
Japan
$411K +$58.8K +283 +16%
BHPW
390
Beverly Hills Private Wealth
California
$401K -$69K -332 -14%
SCM
391
Sterling Capital Management
North Carolina
$395K +$417K +2,006 New
M&T Bank
392
M&T Bank
New York
$394K +$13.7K +66 +3%
ONB
393
Old National Bancorp
Indiana
$392K +$12.3K +59 +3%
Cambridge Investment Research Advisors
394
Cambridge Investment Research Advisors
Iowa
$390K +$19.3K +93 +5%
ECM
395
ExodusPoint Capital Management
New York
$390K +$411K +1,979 New
PP
396
Prudential plc
United Kingdom
$390K
TMAM
397
Tokio Marine Asset Management
Japan
$390K +$4.99K +24 +1%
BTI
398
Blue Trust Inc
Georgia
$388K +$86.9K +418 +29%
EA
399
Everpar Advisors
Oklahoma
$385K -$81.9K -394 -17%
OAM
400
Ostrum Asset Management
France
$384K +$4.99K +24 +1%

CRL Hedge Fund Activity: Q3 2024 in Review

627 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q3 2024, worth a combined $10.3B — down 5.2% from $10.8B a quarter earlier.

Sellers outnumbered buyers: 97 funds closed out of CRL and 66 opened new positions — a net loss of 31 holders — while 273 trimmed existing stakes and 204 added.

The largest buyer was Wellington Management Group, adding an estimated $777M. The largest seller was BlackRock, cutting an estimated $177M.

  • 627 institutional investors held Charles River Laboratories (CRL) as of Q3 2024, down from 664 in Q2 2024.
  • Funds reported $10.3B of Charles River Laboratories stock for Q3 2024, down 5.2% quarter-over-quarter.
  • 66 funds opened new Charles River Laboratories positions in Q3 2024 and 97 closed out, a net change of -31 holders.
  • The largest Charles River Laboratories buyer in Q3 2024 was Wellington Management Group, an estimated $777M added.
  • The largest Charles River Laboratories seller in Q3 2024 was BlackRock, an estimated $177M sold.

Based on aggregated 13F filings for Q3 2024.